AbbVie would gain an experimental eczema drug by buying biotech: report

Finance
by
4 hours ago 0 1

AbbVie is reportedly trying to buy a biotech company that is developing a promising atopic dermatitis drug for $10.9 billion in cash, according to a Financial Times report.

Latest News
Finance
The initial SpaceX frenzy is cooling off — but a new wave of cash is waiting to strike
3 hours ago
0 1
Finance
‘Money can make you happy’: My wife and I have no heirs, but we’re making the world a better place by giving it away
5 hours ago
0 0
Finance
DHL transitions Zelostech autonomous vehicles to live Singapore hub ops
7 hours ago
0 2

Leave a Reply

Your email address will not be published. Required fields are marked *

Recent Comments

No comments to show.

© Copyright 2026 Glen Dross | Powered by WordPress | Mercury Theme
© Copyright 2026 Glen Dross
Powered by WordPress | Mercury Theme

Powered by
►
Necessary cookies enable essential site features like secure log-ins and consent preference adjustments. They do not store personal data.
None
►
Functional cookies support features like content sharing on social media, collecting feedback, and enabling third-party tools.
None
►
Analytical cookies track visitor interactions, providing insights on metrics like visitor count, bounce rate, and traffic sources.
None
►
Advertisement cookies deliver personalized ads based on your previous visits and analyze the effectiveness of ad campaigns.
None
Powered by